PAI-1

Liquid. In 150 mM NaCl, 50 mM sodium phosphate buffer, 1 mM EDTA, pH 6.6. AVOID FREEZE/THAW CYCLES. PAI-1 is the primary inhibitor of both tissue plasminogen activator (tPA) and urokinase (uPA). PAI-1 can exist either in an active inhibitory conformation or in an inactive or latent conformation. This highly purified preparation has not been exposed to denaturing conditions and has been chromatographically purified of latent material. PAI-1 is a marker for acute myocardial infarction and several thrombolytic disorders. Protects platelets against the inhibitory effects of plasma. Reported to be an important prognostic factor in breast cancer patients. PAI-1 is highly stable when stored at or below pH 6.6. Biological activity: ≥90% by uPA assay. Purity: ≥98% by SDS-PAGE.

Ref.: Vaughan, D.E., et al. 1995. J. Clin. Invest. 95, 995. Dimitri, G., et al. 1993. Boll. Chim. Farmaceutico 132, 272. Janicke, F., et al. 1993. Breast Cancer Res. Treatment 24, 195. Klasser, K.J., et al. 1993. Coron. Artery Dis. 4, 713. Robbie, L.A., et al. 1993. Thromb. Hemost. 70, 307. Lawrence, D., et al. 1989. Eur. J. Biochem. 186, 523. Collen, D. and Lijnen, H.R. 1987. In The Molecular Basis of Blood Diseases (Stamatoyannopoulus, G., et al. Eds.) W.B. Saunders Ginsberg, D., et al. 1986. J. Clin. Invest. 78, 1673. Vassalli, J.D., et al. 1985. J. Cell Biol. 100, 86.